Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 179

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 179
---
 Mr. Silverman. |

105

Each of the committees has a written charter adopted by the Board; a current copy of each such charter is available in the “Investor Relations” section on our website at http://www.petrospharma.com/investors. Audit Committee Our Audit Committee provides oversight of our accounting and financial reporting process, the audit of our financial statements and our internal control function. Among other matters, the Audit Committee is responsible for the following:

| ● | appointment, compensation, retention and oversight the independent auditor’s services to the Company; |

| ● | reviewing the scope of the annual audit and non-audit services of the independent auditor; |

| ● | reviewing and discussing with management and the independent auditor the results of the annual audit and the review of our quarterly financial statements, including the disclosures in our annual and quarterly reports filed with the SEC; |

| ● | evaluating the independence of the independent auditors; |

| ● | evaluating and discussing with management the adequacy and effectiveness of the Company’s accounting and internal control policies and procedures; |

| ● | reviewing our risk assessment and risk management processes; and |

| ● | establishing and overseeing procedures for receiving, retaining and the treatment of complaints received by us regarding accounting, internal accounting controls or audit matters. |

The Audit Committee held four meetings in 2024. All members of our Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our Board has determined that Mr. Bernstein is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication under the applicable rules and regulations of Nasdaq. All of the members of our Audit Committee are independent directors as defined under the applicable rules and regulations of the SEC and Nasdaq. Compensation Committee The Compensation Committee, among other things, (i) oversees the Company’s compensation plans and practices with respect to the Company’s executive officers and directors, (ii) evaluates the performance of the executive officers of the Company, and (iii) reviews the Company’s stock and incentive compensation plans and recommends changes in such plans to the Board as needed. The Compensation Committee held one meeting in 2024. The Board has determined that each member of the Compensation Committee is an independent director in accordance with the rules of The Nasdaq Stock Market and applicable federal securities laws and regulations. Nominating and Corporate Governance Committee The Nominating and Corporate Governance Committee assists the Board in, among other things; (i) identifying individuals qualified to become members of the